Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

World Patent Ratings Releases Details of Conference Call on Transparency and Intangible Asset Valuation in the Biotechnology Industry
  • USA - English


News provided by

World Patent Ratings

Jan 02, 2017, 22:30 ET

Share this article

Share toX

Share this article

Share toX

World Patent Ratings Releases Details of Conference Call On Transparency and Intangible Asset Valuations in Biotech
World Patent Ratings Releases Details of Conference Call On Transparency and Intangible Asset Valuations in Biotech

Miami Beach, Florida (PRWEB) January 02, 2017 -- World Patent Ratings, a specialized rating agency and expert network focused on intangible asset valuation, has issued the details of conference call focused on intangible asset valuations in biotech. World Patent Ratings has been a pioneer in calling attention to the irrational valuation of intangible assets held on corporate balance sheets around the world. Through the world’s largest repository of intangible asset data, the company has been able to bring standardization and objective measure to an outdated financial reporting system.

"Biotech companies just had their worst year in more than a decade," said Scott Cooper, CEO of the World Patent Family of Companies. "We don't expect the trend to reverse in 2017. Transparency is a huge concern in the reporting of intangible assets..."

Post this

The company's Board includes notable figures such as Ambassador Dell Dailey, Former Navy Vice Admiral Al Konetzni, former US Attorney Matthew Whitaker, General Nitzan Nuriel of the Israel Defense Forces, Dr. Aileen Marty, and Scott Cooper, CEO of the World Patent Family of Companies and Director of The Cooper Idea Foundation.

World Patent Ratings Membership can be achieved through four different levels of affiliation including: Member, Premier Member, Trusted Partner and Accredited Partner Status. World Patent Ratings provides research reports, offers continuing professional education, and consulting services surrounding the financial reporting of intangible assets.

The “World Patent Rating” online seal enhances marketplace trust and confidence in financial reporting. It displays a company’s commitment to transparency and integrity in the valuation of intangible assets.

"Biotech companies just had their worst year in more than a decade." said Scott Cooper, CEO of the World Patent Family of Companies, "We don't expect the trend to reverse in 2017. Transparency is a huge concern in the reporting of intangible assets in this volatile sector."

World Patent Ratings utilizes the planet’s largest specialized repository of open source intangible asset and patent data. The company's team of data scientists has used code from over hundreds of worldwide open data sources, including the Central Intelligence Agency, the Securities and Exchange Commission, Google, Yahoo, The New York Times, the World Health Organization, UNICEF, Amazon, Facebook, the US Census Bureau, the European Union, Pew Research Center, and the National Climactic Data Center.

World Patent Ratings has initiated coverage on 100 Biotech Companies listed below:

Amgen Inc, Gilead Sciences Inc, AbbVie Inc, Celgene Corp, Biogen Inc, Alexion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Vertex Pharmaceuticals Inc, United Therapeutics Corp, Juno Therapeutics Inc, Fortress Biotech Inc, Xencor Inc, aTyr Pharma Inc, Audentes Therapeutics Inc, Genomic Health Inc, Dicerna Pharmaceuticals Inc, Corvus Pharmaceuticals Inc, Genocea Biosciences Inc, Bellicum Pharmaceuticals Inc, XBiotech Inc, Mirna Therapeutics Inc, Recro Pharma Inc, Cleveland Biolabs Inc, Cancer Genetics Inc, Ra Pharmaceuticals Inc, ADMA Biologics Inc, Bioptix Inc, Brainstorm Cell Therapuetics Inc, PharmAthene Inc, Cellular Biomedicine Group Inc, Vericel Corp, Cytori Therapeutics Inc, Viking Therapeutics Inc, Proteostasis Therapeutics Inc, Capricor Therapeutics Inc, Opexa Therapeutics Inc, OHR Pharmaceutical Inc, VBI Vaccines Inc, IsoRay Inc, Corbus Pharmaceuticals Holdings Inc, Neuralstem Inc, Microbot Medical Inc, Protagonist Therapeutics Inc, Enzon Pharmaceuticals Inc, Heat Biologics Inc, Stellar Biotechnologies Inc, Neurotrope Inc, Signal Genetics Inc, Rxi Pharmaceuticals Corp, OncoCyte Corp, CohBar Inc, GlobeImmune Inc, Cellceutix Corp, ImmuCell Corp, AVAX Technologies Inc, Affymax Inc, Anterios Inc, Manhattan Scientifics Inc, Bioqual Inc, CASI Pharmaceuticals Inc, Oragenics Inc, Soligenix Inc, Eiger BioPharmaceuticals Inc, Interleukin Genetics Inc, Aptevo Therapeutics Inc, Immune Pharmaceuticals Inc, Poniard Pharmaceuticals Inc, Orgenesis Inc, MabVax Therapeutics Holdings Inc, Antriabio Inc, Cellectar Biosciences Inc, Unigene Laboratories Inc, Gemphire Therapeutics Inc, Enumeral Biomedical Holdings Inc, Epicore Bionetworks Inc, PhaseRx Inc, Matinas BioPharma Holdings Inc, CEL-SCI Corp, Vaccinogen Inc, Inspyr Therapeutics Inc, MaxCyte Inc, Oncobiologics Inc, Diffusion Pharmaceuticals Inc, PharmaCyte Biotech Inc, CTD Holdings Inc, Helix BioMedix Inc, Harbor Diversified Inc, AquaBounty Technologies Inc, Myrexis Inc, Islet Sciences Inc, Chemtrak Inc, Resolute Oncology Inc, Geovax Labs Inc, Capstone Therapeutics Corp, Longport Inc, Fennec Pharmaceuticals Inc, Sevion Therapeutics Inc, Marina Biotech Inc, OncBioMune Pharmaceuticals Inc, Accelerated Pharma Inc, AzurRx BioPharma Inc, AV Therapeutics Inc, and International Stem Cell Corp.

World Patent Ratings is a specialized rating agency and expert network focused on the standardization and objective measure of intangible assets and the valuation of intellectual property. Our in-depth research of financial practices is intended to uncover truth and meaning in data. We aim to guide policymakers and opinion leaders working to modernize the valuation of corporate assets and bring back confidence and accountability to corporate asset valuation in the global marketplace.

In addition, World Patent Ratings, through its expert network offers the following consulting services in the areas of:

1. Patent Valuation
2. Brand Valuation
3. Intellectual Property Litigation Assessment
4. Continuing Professional Education
5. Cyber Security Management
6. Risk Management Compliance
7. Accounting Fraud Prevention Services
8. Emerging Technolgies including Big Data Analytics, Cloud Computing, Artificial Intelligence, Machine
Learning and Deep Learning.

The company has repeatedly warned about the intangible asset bubble. The extreme volatility and the lack of consensus surrounding the accounting of patents and other intangible assets has created a cloud over the global economy. Our mission is to prevent the continued use of creative accounting and a distortion of reported asset values. We are pioneering an accounting revolution geared towards standardization and transparency.

For more information about World Patent Ratings, please visit our website at https://worldpatentratings.com.

Contact World Patent Ratings:

World Patent Ratings
1680 Meridian Avenue, Suite 600
Miami Beach, Florida 33139
(305) 602-8363 Tel

membership(at)worldpatentratings(dot)com

Klaus Nagel, World Patent Ratings, https://worldpatentratings.com, +1 3056028363 Ext: 2, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.